Discover how tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist, is transforming type 2 diabetes care with superior glycemic control, significant weight loss, and next-generation protein–peptide drug design.
Discover how tirzepatide, a next‑generation peptide drug and dual GIP/GLP‑1 receptor agonist, is transforming obesity treatment, improving glycemic control, and reducing cardiometabolic risk through advanced peptide engineering and multi‑receptor targeting.